Natural Alternatives International, Inc. Announces Extension of CarnoSyn® Beta-Alanine License Agreement with Nutrabolt, LLC

Thursday, June 29, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

CARLSBAD, Calif., June 29, 2017 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading

formulator, manufacturer and marketer of customized nutritional supplements, announced today that it has extended to 2026 its worldwide license agreement directed to NAI's CarnoSyn® beta-alanine patent and trademark estate with Nutrabolt,
LLC.   Nutrabolt is the fastest growing nutritional life science company and creator of Cellucor® C4 products, the #1 pre-workout product offering in the market.  The companies are expanding their business relationship to collaborate in the area of sports nutrition and other key fields of growth related to CarnoSyn® beta-alanine.  NAI owns an extensive global IP portfolio covering its CarnoSyn® beta-alanine and SR CarnoSyn® products and has invested significant monies funding research and brand awareness around the world.  Nutrabolt is an industry leader in the area of sports nutrition.  Its predominance in the congested, pre-workout market is unrivaled and offers consumers the most effective "best in class" products.  Nutrabolt's investment in sports nutrition has led to significant business growth and expansion, including the recent acquisition of Scivation Nutrition. 

NAI also announced that the U.S. Patent and Trademark Office has allowed a new patent application directed to a broad range of improved methods of beta-alanine intake, targeting such benefits as delaying muscle fatigue, increasing anaerobic capacity, increasing muscle strength and increasing muscle endurance. This new intellectual property significantly lengthened the patent coverage for CarnoSyn® beta-alanine.  Nutrabolt, given its market dominance and view of the future of nutrition, was a natural business partner for NAI. After months of substantive discussions regarding NAI's intellectual property and the future vision of nutrition in sports and other fields, the parties agreed to combine their efforts to lead the market in future research, development and sales of products using NAI's patented and trademarked CarnoSyn® beta-alanine.

Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI is very excited by the execution of this agreement with Nutrabolt extending its worldwide license to our CarnoSyn® patent and trademark rights. The recent addition of NAI's new patent, directed to a broad range of improved methods of beta-alanine intake, is the future of beta-alanine in sports nutrition."  LeDoux went on to say that "during our meetings with Nutrabolt executives and its research team, we explored other fields of use for CarnoSyn® that NAI holds patent rights to uses beyond sports nutrition and for which it continues to explore through funded research around the world. The opportunity to work with a market leader like Nutrabolt related to CarnoSyn® was an easy decision for us."

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at or

This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or

Web site:


To view the original version on PR Newswire, visit:

SOURCE Natural Alternatives International, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store